Early Phase 1 Muscular Dystrophy Trial, Recruiting NCT06641895 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Muscular Dystrophy
Back to Muscular Dystrophy

Early Phase 1 Muscular Dystrophy Trial, Recruiting

NCT06641895
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The child's parent or legal guardian fully understands what the study involves and agrees to participate by signing a consent form
  • The child is a boy who can walk on his own and is at least 4 years old but not yet 8 years old
  • The child has been diagnosed with Duchenne Muscular Dystrophy (DMD) confirmed by genetic testing
  • The child shows at least one typical sign of DMD, such as weakness in the muscles closest to the body (like hips or shoulders), a waddling walk, unusually large-looking calf muscles, difficulty getting up from the floor (pushing up using hands on legs), or shoulder blades that stick out
  • The child is able to cooperate with movement/physical tests, MRI scans, and a small muscle tissue sample (biopsy) as required by the study

Who may not be able to join:

  • The child has active Hepatitis B, Hepatitis C, or HIV infections (confirm with trial site)
  • The child is currently receiving treatment for Hepatitis B, Hepatitis C, or HIV
  • The child's heart is not pumping blood effectively enough, or they have moderate-to-severe heart failure
  • The child has serious or ongoing irregular heartbeats, or was born with a heart defect
  • The child's heart-related medications or treatments have been changed within 1 month before the study begins
  • The child has a significant liver condition, such as scarring of the liver, high blood pressure in the liver, an enlarged spleen, liver-related brain problems, or certain abnormal findings on liver scans or blood tests that the doctor considers medically important

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Jiwen Wang, Shanghai Children's Medical Center, affiliated to Shanghai Jiao Tong University School of Medicine

Phone: 18916613192

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
25 July 2024
Est. completion
31 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of dose limiting toxicity (DLT) events; The incidence of adverse events (AEs) and serious adverse events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov